The DOI matches its Crossref record.
Saponin adjuvant enhancement of antigen-specific immune responses to an experimental HIV-1 vaccine
Abstract
The adjuvant activity of a single highly purified saponin from the soap bark tree Quillaja saponaria was evaluated by using it as a component in an experimental vaccine containing rHIV-1 envelope protein (HIV-1 160D) adsorbed to alum. BALB/c mice immunized with experimental vaccine formulations containing the saponin adjuvant QS-21 produced significantly higher titers of antibodies than mice vaccinated with only the alum-adsorbed HIV-1 160D. Potent amnestic antibody responses to HIV-1 viral proteins were also induced. Ag-specific proliferative responses to recombinant proteins and to three variants of HIV-1 were significantly increased using QS-21 as an adjuvant. Alum-adsorbed HIV-1 160D failed to induce measurable proliferative responses to inactivated HIV-1 viruses, but group-specific proliferative responses were raised when the QS-21 adjuvant was used in the vaccine formulation. MHC class I restricted CTL specific for the immunodominant V-3 loop were induced but only when the QS-21 adjuvant was included in the vaccine formulation. The production of serine esterase by Ag-activated splenic mononuclear cells, indicating the maturation of precursor CTL, was used as a secondary measure of CTL activity, and this response was also increased. The specificity of antibody responses was not significantly broadened using QS-21; the adjuvant increased the immune recognition of epitopes throughout the HIV-1 glycoprotein 160. However, the specificity of the proliferation and serine esterase responses was broadened, suggesting that the QS-21 augmented cell-mediated immune responses specific for epitopes outside of the V-3 loop. Additionally, the QS-21 adjuvant appeared to induce recognition of weakly immunogenic epitopes that were not recognized using only alum-adsorbed HIV-1 160D. The ability of QS-21 to augment both antibody and cell-mediated immune responses suggests that this adjuvant could be a valuable component in subunit vaccines.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,950
Emerging concepts in the science of vaccine adjuvants
Pulendran, B., S. Arunachalam, P., & O’Hagan, D. T. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00163-y · Cited by 1,385
Pathogenesis of human immunodeficiency virus infection
Levy, J. A. (1993) · Microbiological Reviews · doi:10.1128/mr.57.1.183-289.1993 · Cited by 839
Adjuvants for human vaccines—current status, problems and future prospects
Gupta, R. K., & Siber, G. R. (1995) · Vaccine · doi:10.1016/0264-410x(95)00011-o · Cited by 551
Mechanism of Immunopotentiation and Safety of Aluminum Adjuvants
HogenEsch, H. (2013) · Frontiers in Immunology · doi:10.3389/fimmu.2012.00406 · Cited by 430
Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs
Petrovsky, N. (2015) · Drug Safety · doi:10.1007/s40264-015-0350-4 · Cited by 366
Bae, E.-A., Han, M. J., Choo, M.-K., Park, S.-Y., & Kim, D.-H. (2002) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.25.58 · Cited by 307
Actual and potential applications of and saponins in human and animal nutrition
Cheeke, P. R. (2000) · Journal of Animal Science · doi:10.2527/jas2000.00218812007700es0009x · Cited by 257
MHC Class I–Restricted CTL Responses to Exogenous Antigens
Jondal, M., Schirmbeck, R., & Reimann, J. (1996) · Immunity · doi:10.1016/s1074-7613(00)80255-1 · Cited by 253
Mária, J., & Ingrid, Ž. (2017) · Food & Function · doi:10.1039/c7fo00161d · Cited by 71
Metadata
- Authors
- Wu, J. Y., Gardner, B. H., Murphy, C. I., Seals, J. R., Kensil, C. R., Recchia, J., Beltz, G. A., Newman, G. W., & Newman, M. J.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 1992-03-01
- Volume
- 148
- Issue
- 5
- Pages
- 1519-1525
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W1564933160
- Cited by
- 240
- References
- 0
- FWCI
- 4.09
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.